FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1209-1223 September 22, 2005 Number 12 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Freedman, R. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study.

Methods A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up to 18 months. Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration. The primary aim was to delineate differences in the overall effectiveness of these five treatments.

Results Overall, 74 percent of patients discontinued the study medication before 18 months (1061 of the 1432 patients who received at least one dose): 64 percent of those assigned to olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those assigned to quetiapine, 74 percent of those assigned to risperidone, and 79 percent of those assigned to ziprasidone. The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P<0.001) or risperidone (P=0.002) group, but not in the perphenazine (P=0.021) or ziprasidone (P=0.028) group. The times to discontinuation because of intolerable side effects were similar among the groups, but the rates differed (P=0.04); olanzapine was associated with more discontinuation for weight gain or metabolic effects, and perphenazine was associated with more discontinuation for extrapyramidal effects.

Conclusions The majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons. Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone. Olanzapine was associated with greater weight gain and increases in measures of glucose and lipid metabolism.

Source Information

From the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York (J.A.L.); the Department of Psychiatry, School of Medicine (T.S.S., D.O.P.), and the Department of Biostatistics, School of Public Health (S.M.D., C.E.D.), University of North Carolina at Chapel Hill, Chapel Hill; Quintiles, Research Triangle Park, N.C. (S.M.D.); the Department of Biological Psychiatry, John Umstead Hospital, Butner, N.C. (J.P.M.); the Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, N.C. (J.P.M., M.S.S., R.S.E.K.); the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn. (R.A.R.); and the Division of Services and Intervention Research, National Institute of Mental Health, National Institutes of Health, Bethesda, Md. (B.D.L., J.S., J.K.H.).

Address reprint requests to Dr. Lieberman at the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, or at jlieberman{at}columbia.edu.

Full Text of this Article

Related Letters:

Antipsychotic Drugs and Schizophrenia
Dettling M., Anghelescu I.-G., Essock S. M., Covell N. H., Jackson C. T., Gupta N., Basu D., Duan N., Kraemer H. C., Mintz J., Lieberman J. A., Stroup T. S., Davis S. M., the CATIE Investigator Group
Extract | Full Text | PDF  
N Engl J Med 2006; 354:298-300, Jan 19, 2006. Correspondence

This article has been cited by other articles:

• Norquist, G. S. (2009). Introduction to the STAR*D Special Section. Psychiatr. Serv. 60: 1437-1438 [Full Text]  
• Barbui, C., Cipriani, A., Furukawa, T. A, Salanti, G., Higgins, J. P T, Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M, Geddes, J. R (2009). Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?. Evid. Based Ment. Health 12: 101-104 [Full Text]  
• Kraemer, H. C., Glick, I. D., Klein, D. F. (2009). Clinical Trials Design Lessons From the CATIE Study. Am. J. Psychiatry 166: 1222-1228 [Abstract] [Full Text]  
• Picchioni, M. M., Dazzan, P. (2009). Clinical significance of neurological abnormalities in psychosis. Adv. Psychiatr. Treat. 15: 419-427 [Abstract] [Full Text]  
• Moscarelli, M. (2009). Passive and Active Schizophrenia: Toward a New Descriptive Micropsychopathology. Schizophr Bull 35: 1183-1196 [Abstract] [Full Text]  
• Patel, M. X., Taylor, M., David, A. S. (2009). Antipsychotic long-acting injections: mind the gap. Br. J. Psychiatry 195: S1-S4 [Abstract] [Full Text]  
• Taylor, D. (2009). Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br. J. Psychiatry 195: S13-S19 [Abstract] [Full Text]  
• Haddad, P. M., Taylor, M., Niaz, O. S. (2009). First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br. J. Psychiatry 195: S20-S28 [Abstract] [Full Text]  
• Bogart, G. T, Chavez, B. (2009). Safety and Efficacy of Quetiapine in Bipolar Depression. The Annals of Pharmacotherapy 43: 1848-1856 [Abstract] [Full Text]  
• Varley, C. K., McClellan, J. (2009). Implications of Marked Weight Gain Associated With Atypical Antipsychotic Medications in Children and Adolescents. JAMA 302: 1811-1812 [Full Text]  
• Freudenmann, R. W., Lepping, P. (2009). Delusional Infestation. Clin. Microbiol. Rev. 22: 690-732 [Abstract] [Full Text]  
• Breden, E. L., Liu, M. T., Dean, S. R. (2009). Metabolic and Cardiac Side Effects of Second-generation Antipsychotics: What Every Clinician Should Know. Journal of Pharmacy Practice 22: 478-488 [Abstract]  
• Reeves, R., Kaldany, H., Lieberman, J., Vyas, R. (2009). Creation of a Metabolic Monitoring Program for Second-Generation (Atypical) Antipsychotics. J Correct Health Care 15: 292-301 [Abstract]  
• Ungvari, G. S., Caroff, S. N., Gerevich, J. (2009). The Catatonia Conundrum: Evidence of Psychomotor Phenomena as a Symptom Dimension in Psychotic Disorders. Schizophr Bull 0: sbp105v1-sbp105 [Abstract] [Full Text]  
• Raj, S. R., Stein, C. M., Saavedra, P. J., Roden, D. M. (2009). Cardiovascular Effects of Noncardiovascular Drugs. Circulation 120: 1123-1132 [Full Text]  
• Messer, T, Glaser, T, Landen, H, Schmauss, M (2009). Long-term treatment with flupentixol results of a post-marketing surveillance study. J Psychopharmacol 23: 805-813 [Abstract]  
• Parks, J., Radke, A., Parker, G., Foti, M.-E., Eilers, R., Diamond, M., Svendsen, D., Tandon, R. (2009). Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment. Schizophr Bull 35: 931-936 [Abstract] [Full Text]  
• Rosenheck, R. A., Sernyak, M. J. (2009). Developing A Policy For Second-Generation Antipsychotic Drugs. Health Aff (Millwood) 28: w782-w793 [Abstract] [Full Text]  
• Meltzer, D. O., Basu, A., Meltzer, H. Y. (2009). Comparative Effectiveness Research For Antipsychotic Medications: How Much Is Enough?. Health Aff (Millwood) 28: w794-w808 [Abstract] [Full Text]  
• Mojtabai, R. (2009). Americans' Attitudes Toward Psychiatric Medications: 1998-2006. Psychiatr. Serv. 60: 1015-1023 [Abstract] [Full Text]  
• Meyers, B. S., Flint, A. J., Rothschild, A. J., Mulsant, B. H., Whyte, E. M., Peasley-Miklus, C., Papademetriou, E., Leon, A. C., Heo, M., for the STOP-PD Group, (2009). A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs Olanzapine Plus Placebo for Psychotic Depression: The Study of Pharmacotherapy of Psychotic Depression (STOP-PD). Arch Gen Psychiatry 66: 838-847 [Abstract] [Full Text]  
• Schumock, G. T., Pickard, A. S. (2009). Comparative effectiveness research: Relevance and applications to pharmacy. Am J Health Syst Pharm 66: 1278-1286 [Abstract] [Full Text]  
• Xia, J., Adams, C., Bhagat, N., Bhagat, V., Bhoopathi, P., El-Sayeh, H., Pinfold, V., Takriti, Y. (2009). Losing participants before the trial ends erodes credibility of findings. Psychiatr. Bull. 33: 254-257 [Abstract] [Full Text]  
• Rabinowitz, J., Levine, S. Z., Barkai, O., Davidov, O. (2009). Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features. Schizophr Bull 35: 775-788 [Abstract] [Full Text]  
• Grootens, K. P., van Veelen, N. M. J., Peuskens, J., Sabbe, B. G. C., Thys, E., Buitelaar, J. K., Verkes, R. J., Kahn, R. S. (2009). Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial. Schizophr Bull 0: sbp037v1-sbp037 [Abstract] [Full Text]  
• Lyon, G. J., Abi-Dargham, A., Moore, H., Lieberman, J. A., Javitch, J. A., Sulzer, D. (2009). Presynaptic Regulation of Dopamine Transmission in Schizophrenia. Schizophr Bull 0: sbp010v1-sbp010 [Abstract] [Full Text]  
• Ross, K., Freeman, D., Dunn, G., Garety, P. (2009). A Randomized Experimental Investigation of Reasoning Training for People With Delusions. Schizophr Bull 0: sbn165v1-sbn165 [Abstract] [Full Text]  
• Cascella, N. G., Kryszak, D., Bhatti, B., Gregory, P., Kelly, D. L., Mc Evoy, J. P., Fasano, A., Eaton, W. W. (2009). Prevalence of Celiac Disease and Gluten Sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population. Schizophr Bull 0: sbp055v1-sbp055 [Abstract] [Full Text]  
• Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W. W., Keefe, R. S., Boter, H., Keet, I. P.M., Prelipceanu, D., Rybakowski, J. K., Libiger, J., Hummer, M., Dollfus, S., Lopez-Ibor, J. J., Hranov, L. G., Gaebel, W., Peuskens, J., Lindefors, N., Riecher-Rossler, A., Kahn, R. S. (2009). Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). Am. J. Psychiatry 166: 675-682 [Abstract] [Full Text]  
• Canuso, C. M., Dirks, B., Carothers, J., Kosik-Gonzalez, C., Bossie, C. A., Zhu, Y., Damaraju, C. V., Kalali, A. H., Mahmoud, R. (2009). Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia. Am. J. Psychiatry 166: 691-701 [Abstract] [Full Text]  
• Goodwin, G., Consensus Group of the British Association for Psy, (2009). Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 23: 346-388 [Abstract]  
• Sibitz, I., Unger, A., Woppmann, A., Zidek, T., Amering, M. (2009). Stigma Resistance in Patients With Schizophrenia. Schizophr Bull 0: sbp048v1-sbp048 [Abstract] [Full Text]  
• West, J. C., Wilk, J. E., Rae, D. S., Muszynski, I. S., Stipec, M. R., Alter, C. L., Sanders, K. E., Crystal, S., Regier, D. A. (2009). Medicaid Prescription Drug Policies and Medication Access and Continuity: Findings From Ten States. Psychiatr. Serv. 60: 601-610 [Abstract] [Full Text]  
• Zheng, L., Mack, W. J., Dagerman, K. S., Hsiao, J. K., Lebowitz, B. D., Lyketsos, C. G., Stroup, T. S., Sultzer, D. L., Tariot, P. N., Vigen, C., Schneider, L. S. (2009). Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer's Disease Patients: The CATIE-AD Study. Am. J. Psychiatry 166: 583-590 [Abstract] [Full Text]  
• Horvitz-Lennon, M., Donohue, J. M., Domino, M. E., Normand, S.-L. T. (2009). Improving Quality And Diffusing Best Practices: The Case Of Schizophrenia. Health Aff (Millwood) 28: 701-712 [Abstract] [Full Text]  
• Wang, P. S., Ulbricht, C. M., Schoenbaum, M. (2009). Improving Mental Health Treatments Through Comparative Effectiveness Research. Health Aff (Millwood) 28: 783-791 [Abstract] [Full Text]  
• MacDonald, A. W., Schulz, S. C. (2009). What We Know: Findings That Every Theory of Schizophrenia Should Explain. Schizophr Bull 35: 493-508 [Abstract] [Full Text]  
• Calton, T., Spandler, H. (2009). Minimal-medication approaches to treating schizophrenia. Adv. Psychiatr. Treat. 15: 209-217 [Abstract] [Full Text]  
• Smith, T. E., Sederer, L. I. (2009). A New Kind of Homelessness for Individuals With Serious Mental Illness? The Need for a "Mental Health Home". Psychiatr. Serv. 60: 528-533 [Abstract] [Full Text]  
• Dean, C. E., Thuras, P. D. (2009). Mortality and tardive dyskinesia: long-term study using the US National Death Index. Br. J. Psychiatry 194: 360-364 [Abstract] [Full Text]  
• Healy, D. (2009). Trussed in Evidence? Ambiguities at the Interface between Clinical Evidence and Clinical Practice. Transcultural Psychiatry 46: 16-37 [Abstract]  
• Leibing, A. (2009). Tense Prescriptions? Alzheimer Medications and the Anthropology of Uncertainty. Transcultural Psychiatry 46: 180-206 [Abstract]  
• Haupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R., Newcomer, J. W. (2009). Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated With Second-Generation Antipsychotic Agents. Am. J. Psychiatry 166: 345-353 [Abstract] [Full Text]  
• Correll, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M., Leucht, S. (2009). Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophr Bull 35: 443-457 [Abstract] [Full Text]  
• Mohamed, S., Rosenheck, R., McEvoy, J., Swartz, M., Stroup, S., Lieberman, J. A. (2009). Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. Schizophr Bull 35: 336-346 [Abstract] [Full Text]  
• Linck, V. M., Herrmann, A. P., Piato, A. L., Detanico, B. C., Figueiro, M., Florio, J., Iwu, M. M., Okunji, C. O., Leal, M. B., Elisabetsky, E. (2009). Alstonine as an Antipsychotic: Effects on Brain Amines and Metabolic Changes. Evid Based Complement Alternat Med 0: nep002v1-nep002 [Abstract] [Full Text]  
• Drake, R. E., Wilkniss, S. M., Frounfelker, R. L., Whitley, R., Zipple, A. M., McHugo, G. J., Bond, G. R. (2009). Public-Academic Partnerships: The Thresholds-Dartmouth Partnership and Research on Shared Decision Making. Psychiatr. Serv. 60: 142-144 [Abstract] [Full Text]  
• Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., Davis, J. M. (2009). A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia. Am. J. Psychiatry 166: 152-163 [Abstract] [Full Text]  
• Insel, T. R. (2009). Translating Scientific Opportunity Into Public Health Impact: A Strategic Plan for Research on Mental Illness. Arch Gen Psychiatry 66: 128-133 [Abstract] [Full Text]  
• Smith, M., Porter, R. (2009). Antipsychotics and risk of diabetes in schizophrenia. Br. J. Psychiatry 194: 186-187 [Full Text]  
• Schneeweiss, S., Avorn, J. (2009). Antipsychotic Agents and Sudden Cardiac Death -- How Should We Manage the Risk?. NEJM 360: 294-296 [Full Text]  
• Rohrbaugh, R., Federman, D. G., Borysiuk, L., Sernyak, M. (2009). Utilizing VA Information Technology to Develop Psychiatric Resident Prescription Profiles. Acad. Psychiatry 33: 27-30 [Abstract] [Full Text]  
• Davis, J. M., Leucht, S., Glick, I. D. (2009). CATIE Findings Revisited. Psychiatr. Serv. 60: 125-126 [Full Text]  
• Martin, B. C, Wiley-Exley, E. K, Richards, S., Domino, M. E, Carey, T. S, Sleath, B. L. (2009). Contrasting Measures of Adherence with Simple Drug Use, Medication Switching, and Therapeutic Duplication. The Annals of Pharmacotherapy 43: 36-44 [Abstract] [Full Text]  
• Semple, D., Smyth, R. (2009). Chapter 4 Evidence-based psychiatry. Oxford Handbook of Psychiatry 2: med-9780199239467-chapter-med-9780199239467-chapter [Full Text]  
• Young, A. S., Niv, N., Cohen, A. N., Kessler, C., McNagny, K. (2008). The Appropriateness of Routine Medication Treatment for Schizophrenia. Schizophr Bull 0: sbn138v1-sbn138 [Abstract] [Full Text]  
• Koning, J. P., Tenback, D. E, van Os, J., Aleman, A., Kahn, R. S., van Harten, P. N. (2008). Dyskinesia and Parkinsonism in Antipsychotic-Naive Patients With Schizophrenia, First-Degree Relatives and Healthy Controls: A Meta-analysis. Schizophr Bull 0: sbn146v1-sbn146 [Abstract] [Full Text]  
• Dolder, C. (2008). Review: Paliperidone reduces symptoms of schizophrenia and schizophrenia-like illness. Evid. Based Ment. Health 11: 114-114 [Full Text]  
• Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Maloney, A. E., Michael, E., De Jong, S., Slifka, K., Noyes, N., Hlastala, S., Pierson, L., McNamara, N. K., Delporto-Bedoya, D., Anderson, R., Hamer, R. M., Lieberman, J. A. (2008). Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. Am. J. Psychiatry 165: 1420-1431 [Abstract] [Full Text]  
• Rabinowitz, J., Davidov, O. (2008). A Composite Approach That Includes Dropout Rates When Analyzing Efficacy Data in Clinical Trials of Antipsychotic Medications. Schizophr Bull 34: 1145-1150 [Abstract] [Full Text]  
• Arranz, M. J., Kapur, S. (2008). Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?. Schizophr Bull 34: 1130-1144 [Abstract] [Full Text]  
• Pfeiffer, P. N., Ganoczy, D., Valenstein, M. (2008). Dosing Frequency and Adherence to Antipsychotic Medications. Psychiatr. Serv. 59: 1207-1210 [Abstract] [Full Text]  
• Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., Riggio, S., Chakos, M. H., Swartz, M. S., Keefe, R. S. E., Stroup, T. S., Lieberman, J. A., the Clinical Antipsychotic Trials of Intervention, (2008). Extrapyramidal side-effects of antipsychotics in a randomised trial. Br. J. Psychiatry 193: 279-288 [Abstract] [Full Text]  
• Goudie, A., Cole, J. (2008). Switching antipsychotics. Antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications. J Psychopharmacol 22: 815-817  
• Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X.-M., Mahadik, S. P., Duman, R. S., Porter, J. H., Modica-Napolitano, J. S., Newton, S. S., Csernansky, J. G. (2008). Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection. Pharmacol. Rev. 60: 358-403 [Abstract] [Full Text]  
• Shajahan, P., MacRae, A., Bashir, M., Taylor, M. (2008). Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy. J Psychopharmacol 22: 778-783 [Abstract]  
• Leucht, C., Kitzmantel, M., Chua, L., Kane, J., Leucht, S. (2008). Haloperidol versus chlorpromazine for treatment of schizophrenia. Schizophr Bull 34: 813-815 [Full Text]  
• Hammerman, A., Dreiher, J., Klang, S. H, Munitz, H., Cohen, A. D, Goldfracht, M. (2008). Antipsychotics and Diabetes: An Age-Related Association. The Annals of Pharmacotherapy 42: 1316-1322 [Abstract] [Full Text]  
• Yang, M., Barner, J. C, Lawson, K. A, Rascati, K. L, Wilson, J. P, Crismon, M L., Worchel, J., Mascarenas, C. A (2008). Antipsychotic Medication Utilization Trends Among Texas Veterans: 1997-2002. The Annals of Pharmacotherapy 42: 1229-1238 [Abstract] [Full Text]  
• Savoy, Y. E., Ashton, M. A., Miller, M. W., Nedza, F. M., Spracklin, D. K., Hawthorn, M. H., Rollema, H., Matos, F. F., Hajos-Korcsok, E. (2008). Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation. Schizophr Bull 0: sbn104v1-sbn104 [Abstract] [Full Text]  
• Mohamed, S., Rosenheck, R., Swartz, M., Stroup, S., Lieberman, J. A., Keefe, R. S.E. (2008). Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. Am. J. Psychiatry 165: 978-987 [Abstract] [Full Text]  
• Tyrer, P. (2008). So careless of the single trial. Evid. Based Ment. Health 11: 65-66 [Full Text]  
• Foussias, G., Remington, G. (2008). Negative Symptoms in Schizophrenia: Avolition and Occam's Razor. Schizophr Bull 0: sbn094v1-sbn094 [Abstract] [Full Text]  
• Lang, U., Willbring, M., von Golitschek, R., Schmeisser, A., Matschke, K., Tugtekin, S M. (2008). Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives. J Psychopharmacol 22: 576-580 [Abstract]  
• Halene, T. B., Siegel, S. J. (2008). Antipsychotic-Like Properties of Phosphodiesterase 4 Inhibitors: Evaluation of 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with Auditory Event-Related Potentials and Prepulse Inhibition of Startle. J. Pharmacol. Exp. Ther. 326: 230-239 [Abstract] [Full Text]  
• Leon, A. C. (2008). Implications of Clinical Trial Design on Sample Size Requirements. Schizophr Bull 34: 664-669 [Abstract] [Full Text]  
• Swanson, J. W., Swartz, M. S., Van Dorn, R. A., Volavka, J., Monahan, J., Stroup, T. S., McEvoy, J. P., Wagner, H. R., Elbogen, E. B., Lieberman, J. A., the CATIE investigators, (2008). Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br. J. Psychiatry 193: 37-43 [Abstract] [Full Text]  
• Scott, J. (2008). Cognitive-behavioural therapy for severe mental disorders: back to the future?. Br. J. Psychiatry 192: 401-403 [Abstract] [Full Text]  
• Garety, P. A., Fowler, D. G., Freeman, D., Bebbington, P., Dunn, G., Kuipers, E. (2008). Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. Br. J. Psychiatry 192: 412-423 [Abstract] [Full Text]  
• Shuchman, M. MD, Hebert, P. C. MD MHSc (2008). Bringing a research base to psychiatry. CMAJ 178: 1257-1258 [Full Text]  
• Shuchman, M. MD, Hebert, P. C. MD MHSc (2008). Etablir une base de recherche en psychiatrie. CMAJ 178: 1259-1260 [Full Text]  
• Citrome, L., Jaffe, A., Martello, D., Allingham, B., Levine, J. (2008). Datapoints: Did CATIE Influence Antipsychotic Use?. Psychiatr. Serv. 59: 476-476 [Full Text]  
• Swartz, M. S. (2008). Introduction to the CATIE Special Section. Psychiatr. Serv. 59: 497-499 [Full Text]  
• Swartz, M. S., Stroup, T. S., McEvoy, J. P., Davis, S. M., Rosenheck, R. A., Keefe, R. S. E., Hsiao, J. K., Lieberman, J. A. (2008). What CATIE Found: Results From the Schizophrenia Trial. Psychiatr. Serv. 59: 500-506 [Abstract] [Full Text]  
• Domino, M. E., Swartz, M. S. (2008). Who Are the New Users of Antipsychotic Medications?. Psychiatr. Serv. 59: 507-514 [Abstract] [Full Text]  
• Rosenheck, R. A., Leslie, D. L., Doshi, J. A. (2008). Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making. Psychiatr. Serv. 59: 515-520 [Abstract] [Full Text]  
• Frank, R. G. (2008). Policy Toward Second-Generation Antipsychotic Drugs: A Cautionary Note. Psychiatr. Serv. 59: 521-522 [Full Text]  
• Carpenter, W. T., Buchanan, R. W. (2008). Lessons to Take Home From CATIE. Psychiatr. Serv. 59: 523-525 [Abstract] [Full Text]  
• Covell, N. H., Finnerty, M. T., Essock, S. M. (2008). Implications of CATIE for Mental Health Services Researchers. Psychiatr. Serv. 59: 526-529 [Abstract] [Full Text]  
• Owens, D. C. (2008). What CATIE Did: Some Thoughts on Implications Deep and Wide. Psychiatr. Serv. 59: 530-533 [Abstract] [Full Text]  
• Parks, J. J., Radke, A. Q., Tandon, R. (2008). Impact of the CATIE Findings on State Mental Health Policy. Psychiatr. Serv. 59: 534-536 [Abstract] [Full Text]  
• Law, M. R., Ross-Degnan, D., Soumerai, S. B. (2008). Effect of Prior Authorization of Second-Generation Antipsychotic Agents on Pharmacy Utilization and Reimbursements. Psychiatr. Serv. 59: 540-546 [Abstract] [Full Text]  
• Alessi-Severini, S., Biscontri, R. G., Collins, D. M., Kozyrskyj, A., Sareen, J., Enns, M. W. (2008). Utilization and Costs of Antipsychotic Agents: A Canadian Population-Based Study, 1996-2006. Psychiatr. Serv. 59: 547-553 [Abstract] [Full Text]